Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Study shows experimental thyroid drug reduces cholesterol

An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

12 Mar 2010

Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

12 Mar 2010

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells.

12 Mar 2010

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

BioSante Pharmaceuticals, Inc. today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate).

11 Mar 2010

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced that aggregate revenue of its partner companies for the year was $262 million, up 46% from $179 million in 2008, exceeding the company’s 2009 guidance of $223 million to $243 million, as adjusted to reflect the inclusion of two new partner companies.

11 Mar 2010

Platelet dosage can be lowered in transfusions for cancer and bone-marrow transplant patients

Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding, according to new research involving UT Southwestern Medical Center and 28 other medical institutions.

11 Mar 2010

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Exactly one year to the day after President Obama's historic decision to reverse an eight-year restriction on federally funded embryonic stem cell research, the Children's Hospital Boston Stem Cell Program today announced the development of a unique, comprehensive web site and released a candid video message from its top researchers on the current state of stem cell research to introduce the new site: stemcell.childrenshospital.org.

10 Mar 2010

Alison Walker selected to receive ASH-AMFDP Award

Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation.

10 Mar 2010

Abbott announces definitive agreement to acquire Facet Biotech

Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.

9 Mar 2010

NICE rejects azacitidine for treatment of MDS in patients ineligible for stem cell transplants

A drug for treating a group of conditions that affect the bone marrow is unlikely to be made available on the NHS in England and Wales after the body which provides independent advice on treatments said that it is unlikely to be cost-effective.

8 Mar 2010

Recipients for 2010 Scholar Awards announced

The American Society of Hematology announces the 2010 recipients of its Scholar Awards. The program is designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator.

5 Mar 2010

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis.

5 Mar 2010

RMEI, PIM jointly sponsor virtual lecture to address the need for education on ALL in AYAs

Currently, no definitive standard of care exists for adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL). Recent research suggests that AYAs treated with pediatric treatment protocols have better outcomes than those treated with adult treatment protocols.

5 Mar 2010

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Study shows inhibiting critical genes may halt leukaemia cell growth

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells.

4 Mar 2010

Gene 'addiction' of leukaemia cells

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.

3 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

Study results of new PCR technology that reports mutations associated with FXS announced

Asuragen, Inc. announced today the results of a collaborative study with scientists at the M.I.N.D. Institute at the University of California Davis evaluating a new PCR technology that reproducibly reports mutations associated with Fragile X syndrome (FXS).

2 Mar 2010

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

GTC Biotherapeutics, Inc. announced that it has achieved high-level production of TG20; an anti-CD20 monoclonal antibody (MAb). The TG20 MAb, which is produced in the milk of transgenic goats, is being co-developed by GTC and LFB as part of the LFB-GTC joint venture.

2 Mar 2010

Leukemia News and Research

Further Reading

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Study shows experimental thyroid drug reduces cholesterol

Genentech announces topline results from Phase III trial of Avastin

Eisai's Dacogen five-day dosing regimen for treatment of MDS receives FDA approval

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

Safeguard Scientifics' aggregate partner company revenue rises 46% in 2009

Platelet dosage can be lowered in transfusions for cancer and bone-marrow transplant patients

Children's Hospital Boston develops new web site, releases video message on current state of stem cell research

Alison Walker selected to receive ASH-AMFDP Award

Abbott announces definitive agreement to acquire Facet Biotech

NICE rejects azacitidine for treatment of MDS in patients ineligible for stem cell transplants

Recipients for 2010 Scholar Awards announced

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

RMEI, PIM jointly sponsor virtual lecture to address the need for education on ALL in AYAs

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Study shows inhibiting critical genes may halt leukaemia cell growth

Gene 'addiction' of leukaemia cells

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Study results of new PCR technology that reports mutations associated with FXS announced

GTC Biotherapeutics achieves high-level production of TG20 monoclonal antibody

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News